Welcome to our dedicated page for Connect Biopharma Holdings SEC filings (Ticker: CNTB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotechnology companies like Connect Biopharma reveal critical pipeline information through SEC filings that quarterly earnings alone cannot capture. For CNTB investors tracking Rademikibart's development across atopic dermatitis, asthma, and COPD, understanding these regulatory documents provides insight into the company's progress and financial position.
Connect Biopharma's 10-Q quarterly reports detail cash burn rates and operational runway, essential metrics for evaluating a pre-revenue biotech's ability to fund ongoing clinical trials. These filings break down research and development expenses, providing transparency into where the company allocates resources across its pipeline. Our AI summaries highlight these financial metrics without requiring you to parse through accounting terminology.
8-K filings from Connect Biopharma announce material events including clinical trial milestones, FDA meeting outcomes, and partnership developments with Simcere Pharmaceutical. For a development-stage company, these event-driven disclosures often carry more immediate significance than periodic financial reports. Track when the company reports trial data, regulatory interactions, or corporate structure changes like its ADR termination and direct NASDAQ listing.
Form 4 insider transaction filings show when Connect Biopharma executives and directors buy or sell company shares. In biotechnology, insider trading patterns sometimes precede significant clinical or corporate announcements, making these filings worth monitoring alongside pipeline news.
Access Connect Biopharma's complete SEC filing history with AI-powered explanations that translate complex biotech disclosures into understandable insights. From clinical trial expense breakdowns to licensing agreement terms, find the information that matters for evaluating this IL-4Rα-focused drug developer.
Connect Biopharma (CNTB) reported Q3 2025 results with license and collaboration revenue of $16,000 and total operating expenses of $17.7 million, driven by research and development of $11.1 million and general and administrative of $6.6 million. The company posted a net loss of $17.2 million (basic and diluted loss per share $0.31). For the nine months, revenue was $64,000 and net loss was $40.4 million.
Cash, cash equivalents and short-term investments were $54.8 million as of September 30, 2025. Management believes these resources will fund anticipated needs for at least one year from the filing date. Total shareholders’ equity was $55.4 million.
In September, CNTB terminated its ADR program; ADRs were exchanged one-for-one into ordinary shares, which now trade on Nasdaq under “CNTB.” The company presented rademikibart data at ERS 2025 and is running Phase 2 studies in acute exacerbations of asthma and COPD, with topline data expected in the first half of 2026. As of October 31, 2025, 55,903,513 ordinary shares were outstanding.
Connect Biopharma Holdings Limited filed an 8-K stating it issued a press release announcing financial results for the three and nine months ended September 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference.
Per Item 2.02 and General Instruction B.2, the information, including Exhibit 99.1, is being furnished and not deemed filed under the Exchange Act. The company’s ordinary shares trade on the Nasdaq Global Market under the symbol CNTB.
Connect Biopharma Holdings Ltd (CNTB) filing a Form 144 notifies a proposed sale of 200,000 American Depositary Shares (ADS) on or about 10/01/2025 through Charles Schwab & Co on the Nasdaq Global Market. The ADS block has an aggregate market value of $305,940 and the company reports 55,721,657 shares outstanding. The securities were originally acquired on 03/19/2021 as a stock award issued as compensation, with no cash payment required. The filer reports no sales of issuer securities in the past three months and certifies they are unaware of any undisclosed material adverse information.
Connect Biopharma (CNTB) reported a swing to loss as the company recorded a $23.2 million net loss for the six months ended June 30, 2025, compared with net income of $6.2 million in the prior-year period. Revenue from the Simcere license fell sharply to $48,000 in both the three- and six-month periods from $24.1 million a year earlier, driven by prior upfront and milestone recognition in 2024. Rademikibart progress remains central: the company presented clinical and preclinical data showing rapid FEV1 improvement and reduced exacerbations and reports that its China collaborator submitted an NDA for atopic dermatitis; Connect is eligible for up to $110 million in remaining milestones plus royalties.
Liquidity tightened: cash, cash equivalents and short-term investments totaled $71.8 million at quarter end and management states this is sufficient to meet anticipated cash requirements for at least one year from the filing. Operating cash use increased to $22.6 million for the six months, reflecting higher R&D as Phase 2 acute‑exacerbation trials were initiated and ongoing program investment continued.
Connect Biopharma (CNTB) has initiated the termination of its American Depositary Receipt (ADR) program. On 18 Jul 2025 the company instructed Deutsche Bank Trust Company Americas to end the 18 Mar 2021 Deposit Agreement. All ADRs will be mandatorily cancelled on or about 2 Sep 2025 and exchanged on a 1-for-1 basis for the underlying ordinary shares.
Immediately after cancellation, CNTB plans a direct listing of its ordinary shares on Nasdaq under the same ticker “CNTB,” at which point the ADSs will be delisted. The Depositary will send formal notice to ADS holders describing the exchange mechanics.
The change affects capital-markets logistics rather than operations: it removes depositary fees, simplifies share structure and may broaden investor access, but requires successful coordination with Nasdaq and could create short-term trading friction. No financial results or guidance were provided.
FAQ
What is the current stock price of Connect Biopharma Holdings (CNTB)?
What is the market cap of Connect Biopharma Holdings (CNTB)?
